Ap 与 Tp 方案在 EGFR-TKI 耐药的非小细胞肺癌患者中的
疗效比较
张洁霞;蔡迪;李时悦;占杨清;周承志;秦茵茵;欧阳铭
【期刊名称】《广州医学院学报》 【年(卷),期】2015(000)001 【
摘
要
】
Objective:To
investigate
the
effect
of
AP(pemetrexed+cisplatin)protocol versus
TP(docetaxel+cisplatin)protocol in advanced non-small-cell lung cancer( NSCLC)patients with EGFR-TKI resistance. Methods:The clinical data of 232 advanced NSCLC patients with EGFR-TKI resistance hospitalized in First Affiliated Hospital of Guangzhou Medical university between February 2009 and March 2010 were retrospectively analyzed. Based on different protocols of chemotherapy,all patients were divided into two groups(n= 116 each):the AP(premetrex+cisplatin)group and TP(docetaxel+cisplatin)group. The short-term efficacy[response rate (RR)and disease control rate(DCR)],overall survival(OS),progression free survival(PFS)were evaluated by Response Evaluation Criteria in Solid Tumors(RECIST)criteria. Results:The RR and OS after the targeted drug developed in TP group and AP group were 34.5% vs. 24.1% and 12.4 months vs. 12.0 months,respectively. And there were no statistically significant differences between the two groups(P>0.05). The PFS in TP group and AP group was 8.0 months vs. 6.2 months,with statistically
Ap 与 Tp 方案在 EGFR-TKI 耐药的非小细胞肺癌患者中的疗效比较
